Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

Similar articles for PubMed (Select 21900197)

1.

Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II.

Burton VJ, Holmes AM, Ciuclan LI, Robinson A, Roger JS, Jarai G, Pearce AC, Budd DC.

Blood. 2011 Oct 27;118(17):4750-8. doi: 10.1182/blood-2011-05-347393. Epub 2011 Sep 7.

2.

A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.

Chapman RW, Minnicozzi M, Celly CS, Phillips JE, Kung TT, Hipkin RW, Fan X, Rindgen D, Deno G, Bond R, Gonsiorek W, Billah MM, Fine JS, Hey JA.

J Pharmacol Exp Ther. 2007 Aug;322(2):486-93. Epub 2007 May 11.

3.

Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function.

Burton VJ, Ciuclan LI, Holmes AM, Rodman DM, Walker C, Budd DC.

Blood. 2011 Jan 6;117(1):333-41. doi: 10.1182/blood-2010-05-285973. Epub 2010 Aug 19.

4.

Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.

Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J, Billah M, Dwyer M, Chao J, Deno G, Taveras A, Lundell DJ, Hipkin RW.

J Pharmacol Exp Ther. 2007 Aug;322(2):477-85. Epub 2007 May 11.

5.

Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension.

Hong KH, Lee YJ, Lee E, Park SO, Han C, Beppu H, Li E, Raizada MK, Bloch KD, Oh SP.

Circulation. 2008 Aug 12;118(7):722-30. doi: 10.1161/CIRCULATIONAHA.107.736801. Epub 2008 Jul 28.

6.

Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension.

Yang J, Li X, Al-Lamki RS, Wu C, Weiss A, Berk J, Schermuly RT, Morrell NW.

Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):34-42. doi: 10.1161/ATVBAHA.112.300121. Epub 2012 Nov 8.

7.

Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice.

Long L, MacLean MR, Jeffery TK, Morecroft I, Yang X, Rudarakanchana N, Southwood M, James V, Trembath RC, Morrell NW.

Circ Res. 2006 Mar 31;98(6):818-27. Epub 2006 Feb 23.

8.

The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations.

Dunmore BJ, Drake KM, Upton PD, Toshner MR, Aldred MA, Morrell NW.

Hum Mol Genet. 2013 Sep 15;22(18):3667-79. doi: 10.1093/hmg/ddt216. Epub 2013 May 12.

9.

Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension.

Johnson JA, Hemnes AR, Perrien DS, Schuster M, Robinson LJ, Gladson S, Loibner H, Bai S, Blackwell TR, Tada Y, Harral JW, Talati M, Lane KB, Fagan KA, West J.

Am J Physiol Lung Cell Mol Physiol. 2012 Mar 1;302(5):L474-84. doi: 10.1152/ajplung.00202.2011. Epub 2011 Dec 16.

10.

The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals.

Gordon JR, Li F, Zhang X, Wang W, Zhao X, Nayyar A.

J Leukoc Biol. 2005 Dec;78(6):1265-72. Epub 2005 Oct 4.

11.

BMP type II receptor deficiency confers resistance to growth inhibition by TGF-β in pulmonary artery smooth muscle cells: role of proinflammatory cytokines.

Davies RJ, Holmes AM, Deighton J, Long L, Yang X, Barker L, Walker C, Budd DC, Upton PD, Morrell NW.

Am J Physiol Lung Cell Mol Physiol. 2012 Mar 15;302(6):L604-15. doi: 10.1152/ajplung.00309.2011. Epub 2012 Jan 6.

12.

Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.

Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA, Karoubi G, Courtman DW, Zucco L, Granton J, Stewart DJ.

Circ Res. 2006 Feb 3;98(2):209-17. Epub 2005 Dec 15.

13.

LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.

Aul R, Patel S, Summerhill S, Kilty I, Plumb J, Singh D.

Int Immunopharmacol. 2012 Jul;13(3):225-31. doi: 10.1016/j.intimp.2012.04.008. Epub 2012 May 2.

PMID:
22561413
14.

Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension.

Takahashi H, Goto N, Kojima Y, Tsuda Y, Morio Y, Muramatsu M, Fukuchi Y.

Am J Physiol Lung Cell Mol Physiol. 2006 Mar;290(3):L450-8. Epub 2005 Dec 16.

15.

Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor.

Bertini R, Barcelos LS, Beccari AR, Cavalieri B, Moriconi A, Bizzarri C, Di Benedetto P, Di Giacinto C, Gloaguen I, Galliera E, Corsi MM, Russo RC, Andrade SP, Cesta MC, Nano G, Aramini A, Cutrin JC, Locati M, Allegretti M, Teixeira MM.

Br J Pharmacol. 2012 Jan;165(2):436-54. doi: 10.1111/j.1476-5381.2011.01566.x.

16.

Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice.

Song Y, Coleman L, Shi J, Beppu H, Sato K, Walsh K, Loscalzo J, Zhang YY.

Am J Physiol Heart Circ Physiol. 2008 Aug;295(2):H677-90. doi: 10.1152/ajpheart.91519.2007. Epub 2008 Jun 13. Erratum in: Am J Physiol Heart Circ Physiol. 2009 Oct;297(4):H1544.

17.

Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.

Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, Morrell NW.

Circulation. 2002 Apr 9;105(14):1672-8.

18.

Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension.

Li M, Vattulainen S, Aho J, Orcholski M, Rojas V, Yuan K, Helenius M, Taimen P, Myllykangas S, De Jesus Perez V, Koskenvuo JW, Alastalo TP.

Am J Respir Cell Mol Biol. 2014 Jun;50(6):1118-28. doi: 10.1165/rcmb.2013-0349OC.

PMID:
24433082
19.

BMPR-II deficiency elicits pro-proliferative and anti-apoptotic responses through the activation of TGFβ-TAK1-MAPK pathways in PAH.

Nasim MT, Ogo T, Chowdhury HM, Zhao L, Chen CN, Rhodes C, Trembath RC.

Hum Mol Genet. 2012 Jun 1;21(11):2548-58. doi: 10.1093/hmg/dds073. Epub 2012 Mar 2.

20.

Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue.

Sobolewski A, Rudarakanchana N, Upton PD, Yang J, Crilley TK, Trembath RC, Morrell NW.

Hum Mol Genet. 2008 Oct 15;17(20):3180-90. doi: 10.1093/hmg/ddn214. Epub 2008 Jul 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk